Stock ABBVD ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AbbVie Inc. Buenos Aires S.E.

Equities

ABBVD

ARBCOM4603M9

End-of-day quote Buenos Aires S.E.
Other stock markets
 03:30:00 25/06/2024 am IST 		5-day change 1st Jan Change
17.05 USD +0.29% Intraday chart for AbbVie Inc. +0.29% +12.17%
25/06 FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update DJ
25/06 AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
AbbVie Provides U.S. Regulatory Update on ABBV-951
AQ
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update
DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease
MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo
DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy
RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
PR
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
CI
AbbVie Declares Quarterly Dividend
AQ
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15
MT
AbbVie Declares Quarterly Dividend
PR
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024
CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis
MT
US FDA proposes to remove switching study requirement for biosimilars
RE
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
PR
AbbVie Inc. Announces Board of Directors Changes
CI
AbbVie: FDA approval in ulcerative colitis
CF
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PR
U.S. FDA Approves Skyrizi® (Risankizumab-Rzaa) for Ulcerative Colitis, Expanding Abbvie's Portfolio Across Inflammatory Bowel Disease
CI
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis
DJ
Piper Sandler Adjusts Price Target on AbbVie to $190 From $185
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. ABBVD Stock
  5. News AbbVie Inc.